This article is more than 5 years old. Information may no longer be current.

Aton Pharma acquires U.S. marketing rights for Timoptic product line from Merck

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAWRENCEVILLE, N.J. — Aton Pharma has acquired the U.S. marketing rights to the Timoptic product line from Merck, Aton announced in a press release.

Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for treating elevated IOP in patients with ocular hypertension or open-angle glaucoma. The U.S. Timoptic product line includes Timoptic ophthalmic solution, Timoptic in Ocudose and Timoptic-XE. Timoptic in Ocudose is the only preservative-free medication for glaucoma available in the United States, the release said.

Aton also distributes the dry eye medication Lacrisert (hydroxypropyl cellulose ophthalmic insert).

"As we have done with Lacrisert and other Aton products, we will concentrate on enhancing distribution, sampling and reimbursement assistance while increasing patient and provider awareness for Timoptic in Ocudose," Michael G. Wells, chief executive officer of Aton, said in the release.